Timeline

April 2019

  • April 2019, Holigen subsidiary RPK Biopharma, Aljustrel’s site is scheduled to be inspected by the INFARMED to be granted a cultivation licence at the end of May.
  • April 2019, Holigen subsidiary RPK Biopharma, GMP manufacturing inspection of Sintra’s facility is scheduled to be conducted by the INFARMED in early July.

March 2019

  • March 2019, Holigen subsidiary TCann Pty. Ltd., in Australia has completed the construction work at Sydney’s site and is ready to be inspected by the Office of Drug Control, to be granted the permit to cultivate.
  • March 2019, Holigen subsidiary RPK Biopharma, in Portugal has started the construction work at Aljustrel’s site, that is set to be one of the largest outdoor medicinal cannabis cultivation facilities of the world.

February 2019

  • February 2019, Holigen subsidiary RPK Biopharma, in Portugal has been granted medicinal cannabis cultivation licence by the INFARMED.
  • February 2019, Holigen subsidiary RPK Biopharma, in Portugal has been approved to import the genetics into its facility. The genetics are expected to be in RPK’s facility by the end of February.

January 2019

  • January 2019, Holigen subsidiary RPK Biopharma, officially opened its new facility in Sintra, Portugal with a new team in place. Sintra’s facility is expected to produce 2,5 tons of dried cannabis/year, with additional processing capacity of 40 tons per year.

December 2018

  • December 2018, Holigen partners with Flowr, a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Proposes Regulations (ACMPR). Flowr is a leading cultivator founded by MedReleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists.
  • December 2018, Holigen subsidiary RPK Biopharma, in Portugal has passed INFARMED’s cultivation inspection and now awaits issue of its cultivation licence.

November 2018

  • November 2018, Holigen subsidiary RPK Biopharma, in Portugal announced Holigen’s investment in Aljustrel, Alentejo area-
  • November 2018, Holigen subsidiary TCann Pty. Ltd., in Australia has been granted medicinal cannabis manufacture licence by the Office of Drug Control.

October 2018

  • October 2018, Holigen subsidiary TCann Pty. Ltd., in Australia has been granted a GMP licence to manufacture therapeutic goods by the Office of Drug Control.

September 2018

  • September 2018, Holigen subsidiary TCann Pty. Ltd., in Australia have passed GMP inspection and now await issue of their GMP licence in October.
  • September 2018, Holigen subsidiary TCann Pty. Ltd., in Australia have passed NSW Health’s first stage of assessment for their Schedule 8 pharmaceutical manufacturing licence and are now awaiting an inspection date.
  • September 2018, Holigen announces their intention to open their first non-founder capital raising in order to start the biggest indoor and outdoor licensed grow in Europe with and estimated capacity to produce 700 tonnes of dried Medicinal Cannabis (CBD and THC) per annum. Probably the largest licensed capacity in the world.

August 2018

  • August 2018, Holigen subsidiary RPK BioPharma in Portugal acquires its first 5,000m2 site with warehouse and factory premises in Lisbon and now awaits its licence to cultivate, manufacturing, wholesale and store, seed and finished product in October.

July 2018

  • July 2018, Holigen subsidiary RPK BioPharma in Portugal is given it first inspection date by INFARMED for manufacture. Time to start building out.

June 2018

  • June 2018, Holigen subsidiary RPK BioPharma in Portugal has been granted the prestigious status of Project of National Interest (PIN) by the Portuguese Government – The first in Europe. RPK has had its Government PIN Facilitator appointed.
  • June 2018, Holigen subsidiary RPK BioPharma in Portugal is given it first inspection date by INFARMED for cultivation.

May 2018

  • May 2018, Holigen subsidiary RPK BioPharma collaborates with the prestigious and respected Champalimaud biomedical research Foundation in Portugal to begin research into the therapeutic benefits of Medicinal Cannabis for their patients and to participate in international research.

April 2018

  • April 2018, Holigen subsidiary RPK BioPharma in Portugal lodges application to INFARMED, for cultivation, manufacturing and distribution for a facility with up to 3 Hectare indoor grow and up to 65 Hectare outdoor grow, as well as 1 hectare of processing and GMP manufacturing building “authorised” for Cannabis Sativa L. as well as import and export. THIS IS MOST LIKELY THE LARGEST LICENSED CULTIVATION CAPACITY IN THE WORLD.
  • April 2018, Holigen subsidiary RPK BioPharma supports the Portuguese Government in their preparations to legalise Medicinal Cannabis in Portugal which means that RPK can now distribute and export across Europe and the Euro-zone.

March 2018

  • March 2018, TCann and Anspec meet with the Minister for Health Greg Hunt and agree to provide 24-hour secure delivery to pharmacies in support of the government’s plans to open-up, and to speed-up, access to Medicinal Cannabis for all doctors in Australia. Another win for Holigen.
  • March 2018, Holigen receives letters of engagement from two of Germany’s largest pharmaceutical distributors for sale of Medicinal Cannabis from Portugal to Germany giving Holigen access to over 10,500 pharmacies.
  • March 2018, Holigen subsidiary RPK BioPharma in Portugal completes its package of fully serviced and, local government approved, agricultural and industrial land ready to receive legal authorisation from the Portuguese Government for the cultivation and manufacture of Medicinal Cannabis.
  • 31st March 2018, Holigen subsidiary TCann Pty. Ltd., in Australia achieves licence to cultivate Medicinal Cannabis in NSW for sale and manufacture.
  • 31st March 2018, Holigen subsidiary TCann Pty. Ltd., in Australia achieves licence to research and develop Medicinal Cannabis and associated end products in NSW.

December 2017

  • December 2017, Holigen subsidiary TCann Pty. Ltd., in Australia imports compliant (to TGA’s Therapeutic Goods Order-93) Medicinal Cannabis oils in 3 formulations – High THC, 1:1 mix THC/CBD, and High CBD and commences its sales revenue stream.
  • December 2017, Holigen partners with Anspec Pty. Ltd., the largest wholesaler of Medicinal Cannabis in Australia, for nationwide and international distribution of its Medicinal Cannabis Oils with immediate plans to import three different brands of Medicinal Cannabis including both oil and capsule delivery methods.